ksn.com

PreludeDx™ Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study ...
Morningstar

PreludeDx Study Demonstrates Superiority of DCISionRT® Over Clinicopathology Factors and Criteria for DCIS Treatment Management

LAGUNA HILLS, Calif., July 31, 2025 /PRNewswire/ -- PreludeDx™, a leader in breast cancer precision diagnostics, today announced the publication of new groundbreaking data in the International Journal ...
East Oregonian

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...
WRAL

New Duke study could mean fewer with early-stage breast cancer would face surgery, radiation

A newly released study is challenging the way doctors commonly treat patients with ductal carcinoma in situ (DCIS), known as stage zero breast cancer. DCIS cancer cells are confined inside a milk duct ...
The Victoria Advocate

PreludeDx Announces Groundbreaking Study Results on HER2-Positive DCIS Patients

LAGUNA HILLS, Calif., Oct. 2, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results of a cutting-edge study in ...
La Grande Observer

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...
ksn.com

UPDATE - PreludeDx Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study ...